Retina360: Advances in the Management of Retinal Disease

1.00 CME
1.00 CME WITH ABO CONTINUING CERTIFICATION
60 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Faculty Photo

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by independent medical education grants from Adverum Biotechnologies, Inc.; Alcon Vision, LLC; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Optos, Inc.; Regeneron Pharmaceuticals, Inc.; and REGENXBIO Inc.


Activity Description

Advances in the management and treatment of retinal diseases continue to evolve through refinement of treatment protocols as well as the clinical evaluation of novel and emerging therapies. Keeping abreast of these innovations in disease management and their subsequent incorporation into clinical practice can be challenging, but are necessary to enhance visual acuity and improve patient outcomes. In this continuing medical education activity, experts in the field review recent advances in retinal imaging, as well as the surgical and therapeutic management of retinal diseases. Current and emerging treatment options for diabetic macular edema, diabetic retinopathy, neovascular age-related macular degeneration, retinal vein occlusion, and uveitis will be discussed.


Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal disease.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review recent innovations in imaging for the diagnosis and monitoring of retinal diseases.
  • Assess the evidence on safety and efficacy to optimize the use of conventional, new, and emerging medical treatments for retinal diseases.
  • Evaluate new technology and techniques used to improve outcomes in patients undergoing vitreoretinal surgery.

Activity Chair

Rishi P. Singh, MD
Staff Physician
Center for Ophthalmic Bioinformatics
Cole Eye Institute
Cleveland Clinic Foundation
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH


Faculty

Sophie J. Bakri, MD
Lester T. Jones Endowed Chair
Division of Oculofacial Plastic & Reconstructive Surgery
Professor of Ophthalmology
Mayo Clinic
Rochester, MN

Dilsher S. Dhoot, MD
Vitreoretinal Surgeon
California Retina Consultants
Santa Barbara, CA

Debra A. Goldstein, MD
Magerstadt Professor of Ophthalmology
Director, Uveitis Service
Director, Uveitis Fellowship
Department of Ophthalmology
Northwestern University Feinberg School of Medicine
Chicago, IL

Allen C. Ho, MD
Professor of Ophthalmology
Thomas Jefferson University
Attending Surgeon
Wills Eye Institute
Mid Atlantic Retina
Philadelphia, PA

Caesar K. Luo, MD, FACS, FCPP
Partner, Bay Area Retina Associates
Walnut Creek, CA

Nathan C. Steinle, MD
California Retina Consultants
Santa Barbara, CA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, July 21, 2021, to July 20, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 5 of 7 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Rishi P. Singh, MD
Consulting Fee:Alcon, Apellis, Genentech, Gyroscope, Novartis, Regeneron, Zeiss
Contracted Research: Aerie, Apellis, Graybug Vision

Sophie J. Bakri, MD
Consulting Fee:Adverum, Allergan, Alimera, EyePoint, Genentech, Kala, Novartis, Roche, Zeiss

Dilsher S. Dhoot, MD
Consulting Fee: Alimera, Allegro, Allergan, Bayer, EyePoint, Genentech, Novartis, Regeneron, Santen
Speakers Bureau: Alimera, EyePoint, Genentech, Novartis, Regeneron
Ownership Interest: Vortex Surgical

Debra A. Goldstein, MD
Consulting Fee: Allergan, Bausch + Lomb

Allen C. Ho, MD
Consulting Fee: Adverum, Aerie, AGTC, Alcon, Aldeyra, Allergan, Apellis, AsclepiX, Beaver-Visitec, BioTime, Chengdu Kanghong, Genentech, Graybug, Gyroscope, Iridex, Iveric/Ophthotech, J&J Vision, Lineage/BioTime, Notal Vision, Ocular Therapeutix, ONL, Optovue, PanOptica, Regeneron, Regenxbio
Contracted Research: Aerie, AGTC, Alcon, Aldeyra, Allergan, Apellis, BioTime, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, Iveric/Ophthotech, J&J Vision, Lineage, BioTime, Lumithera, National Eye Institute, Novartis, Optovue, ProGR, Regeneron, Regenxbio, Sanofi
Ownership Interest: Covalent Medical, ONL, PanOptica

Caesar K. Luo, MD, FACS, FCPP
Speakers Bureau: Alimera, Regeneron
Contracted Research: Allergan

Nathan C. Steinle, MD
Consulting Fee: Alimera, Apellis, Genentech, Novartis, Opthea, Regeneron, Regenxbio, Vortex Surgical, Zeiss
Speakers Bureau: Alimera, Genentech, Novartis, Notal Vision, Regeneron
Contracted Research: Genentech, Novartis, Regeneron, Regenxbio, Zeiss
Ownership Interest: Regeneron, Vortex Surgery

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com